Pheno Therapeutics
Develops GPR17-targeting neuroprotective therapeutics for patients with multiple sclerosis and other neurological disorders
Highlights
- New on EvolcAdded 2026-10-31
About Pheno Therapeutics
Pheno Therapeutics is a clinical-stage biotechnology company developing GPR17 antagonists for neurodegenerative and demyelinating disorders. Its research focuses on therapeutically targeting oligodendrocytes to support the brain’s endogenous repair systems.
Its therapeutic focus includes multiple sclerosis, Alzheimer’s disease, ALS, Parkinson’s disease and rare neurological disorders. The company is based in Edinburgh, UK, and was founded in 2018.
Product: GPR17 antagonist therapeutics targeting neurodegenerative and demyelinating disorders.
Jobs at Pheno Therapeutics
More biotech & pharma companies
Phoremost
Biotech developing oral small-molecule cancer drugs, lead programme PMC-001 for primary and metastatic brain cancersNew on EvolcPhynova Group
Develops plant-derived health ingredients, including Reducose for blood glucose, for supplement, food and beverage makersNew on EvolcPlaquetec
Coronary artery disease endotyping and biomarker discovery for drug developers, using in-vivo plaque samplingNew on EvolcPlethora Solutions
Speciality pharma developing and marketing urology treatments, led by an EU-authorised drug for premature ejaculationNew on EvolcProkarium
Microbial immunotherapy platform built on a proprietary bacterial strain (ZH9) for solid tumour treatmentsNew on EvolcProtein Stable
Microplate instruments for protein characterisation used by scientists in academia and biotechnologyNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Recruitee
- WordPress
- jQuery
- nginx